146 related articles for article (PubMed ID: 21070496)
1. Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A.
Dmoszynska A; Hellmann A; Baglin T; O'Shaugnessy D; Trelinski J; Kuliczkowski K; Kloczko J; Hay C; Zawilska K; Makris M; Shaikh-Zaidi R; Gascoigne E; Dash C
Haemophilia; 2011 Mar; 17(2):185-90. PubMed ID: 21070496
[TBL] [Abstract][Full Text] [Related]
2. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
Deitcher SR; Tuller J; Johnson JA
Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A.
Matysiak M; Bobrowska H; Balwierz W; Chybicka A; Kowalczyk JR; Shaikh-Zaidi R; Gillanders K; Dash CH
Haemophilia; 2011 Sep; 17(5):737-42. PubMed ID: 21699629
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
Klukowska A; Windyga J; Batorova A
Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
[TBL] [Abstract][Full Text] [Related]
5. Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgery.
Hay CR; Hellmann A; Dmoszynska A; Baglin T; O'Shaunessey D; Makris M; Shaikh-Zaidi R; Dash CH
Haemophilia; 2011 May; 17(3):428-32. PubMed ID: 21371182
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease.
Morfini M; Mannucci PM; Tenconi PM; Longo G; Mazzucconi MG; Rodeghiero F; Ciavarella N; De Rosa V; Arter A
Thromb Haemost; 1993 Aug; 70(2):270-2. PubMed ID: 8236134
[TBL] [Abstract][Full Text] [Related]
9. Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A.
Dmoszynska A; Kuliczkowski K; Hellmann A; Trelinski J; Kloczko J; Baglin T; Hay C; O'Shaughnessy D; Zawilska K; Makris M; Shaikh-Zaidi R; Gascoigne E; Dash C
Haemophilia; 2011 May; 17(3):456-62. PubMed ID: 21371184
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII.
El-Ekiaby M; Goubran HA; Radosevich M; Abd-Allah A; El-Ekiaby A; Burnouf T
Haemophilia; 2011 Sep; 17(5):e884-8. PubMed ID: 21371202
[TBL] [Abstract][Full Text] [Related]
11. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
[TBL] [Abstract][Full Text] [Related]
12. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
[TBL] [Abstract][Full Text] [Related]
13. Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model.
Raquet E; Stockschläder M; Dickneite G
Haemophilia; 2011 Sep; 17(5):808-14. PubMed ID: 21726357
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study.
Nemes L; Lissitchkov T; Dobaczewski G; Klukowska A; Komrska V; Zimmermann R; Auerswald G; Engl W; Abbühl B; Pavlova BG; Ehrlich HJ
Acta Haematol; 2008; 119(2):89-97. PubMed ID: 18305381
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome.
Luboshitz J; Lubetsky A; Schliamser L; Kotler A; Tamarin I; Inbal A
Thromb Haemost; 2001 May; 85(5):806-9. PubMed ID: 11372672
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia A.
Nemes L; Lissitchkov T; Klukowska A; Dobaczewski G; Komrska V; Zimmermann R; Auerswald G; Engl W; Pavlova B; Abbühl B; Ehrlich HJ
Haemophilia; 2007 Jan; 13(1):9-11. PubMed ID: 17212718
[TBL] [Abstract][Full Text] [Related]
17. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product.
Yee TT; Williams MD; Hill FG; Lee CA; Pasi KJ
Thromb Haemost; 1997 Sep; 78(3):1027-9. PubMed ID: 9308748
[TBL] [Abstract][Full Text] [Related]
18. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
[TBL] [Abstract][Full Text] [Related]
20. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
Berntorp E; Windyga J;
Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]